How many employees does ImmunityBio, Inc. have?

ImmunityBio, Inc. reported 691 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 23, 2026. That is up 1.6% from a year earlier.

What is ImmunityBio, Inc.'s revenue per employee?

ImmunityBio, Inc. brought in $113M of revenue in fiscal Dec 2025, which is $164K per employee. That ranks 33 of 39 companies we track in Biotechnology, where the median is $602K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

ImmunityBio, Inc. employees and revenue per employee

IBRX · Biotechnology · $10.8B market cap

ImmunityBio, Inc. had 691 employees at the end of fiscal Dec 2025, up 1.6% from a year earlier. Revenue for the year was $113M, up 668.3% from a year earlier, or $164K per employee. Revenue and headcount both grew, and revenue grew faster.

Employees

691

+1.6% YoY

Revenue

$113M

+668.3% YoY

Revenue / employee

$164K

Peer median $602K

Rank in industry

33 of 39

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2016

Hover a year for the numbers.

IBRX employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Dec 2025	691	$113M	$164K	+1.6%	+668.3%
Dec 2024	680	$14.7M	$22K	+8.3%	+2270.6%
Dec 2023	628	$622,000	$1K	-13.4%	+159.2%
Dec 2022	725	$240,000	$331	+23.5%	-74.3%
Dec 2021	587	$934,000	$2K	+243.3%	+54.4%
Dec 2020	171	$605,000	$4K	+15.5%	+1307.0%
Dec 2019	148	$43,000	$291	-8.1%	-8.5%
Dec 2018	161	$47,000	$292	+15.8%	+4.4%
Dec 2017	139	$45,000	$324	+69.5%	+2.3%
Dec 2016	82	$44,000	$1K	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

ImmunityBio, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

Company	Employees	Revenue	Revenue / employee	Shape
AMLX Amylyx Pharmaceuticals, Inc.	123	$87.4M	$710K	Contracting
ADPT Adaptive Biotechnologies Corporation	624	$277M	$444K	Efficient growth
RCUS Arcus Biosciences, Inc.	601	$247M	$411K	Contracting
TWST Twist Bioscience Corporation	979	$377M	$385K	Efficient growth
PTGX Protagonist Therapeutics, Inc.	132	$46.0M	$349K	Hiring into decline
NUVB Nuvation Bio Inc.	298	$62.9M	$211K	Efficient growth
KYMR Kymera Therapeutics, Inc.	238	$39.2M	$165K	Hiring into decline
IBRX ImmunityBio, Inc.	691	$113M	$164K	Efficient growth
CYTK Cytokinetics, Incorporated	673	$88.0M	$131K	Efficient growth

Every Healthcare company

Questions about ImmunityBio, Inc.

How many employees does ImmunityBio, Inc. have?: ImmunityBio, Inc. reported 691 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 23, 2026. That is up 1.6% from a year earlier.
What is ImmunityBio, Inc.'s revenue per employee?: ImmunityBio, Inc. brought in $113M of revenue in fiscal Dec 2025, which is $164K per employee. That ranks 33 of 39 companies we track in Biotechnology, where the median is $602K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare IBRX with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in ImmunityBio, Inc.'s annual reports (Form 10-K), latest filed February 23, 2026. This is data, not a recommendation to buy or sell IBRX.